GSMs combined with trans-arterial p53-gene-embolization also achieved satisfactory efficacy in treating BCLC stage B HCC as evidenced by favorable survival rates (100% for both 6 and 12 months) and no significant complications (14). Here, TP53 is linked to hepatocellular carcinoma.